First Booster of SARS-COV-2 mRNA Vaccine Is Not Associated With Alloimmunization and Subclinical Injury of Kidney Allograft

Petr, Vojtěch; Zahradka, Ivan; Módos, István; Roder, Matej; Prewett, Adam; Fialová, Markéta; Machkova, Jana; Hruba, Petra; Magicova, Maria; Slavčev, Antonij; Střı́ž, Ilja; Viklický, Ondřej

doi:10.1097/tp.0000000000004421

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a sensitivity analysis was performed where the threshold of anti-HLA antibody positivity was lowered to MFI of >500 because this threshold was also previously used in other studies and can be considered conservative. 7 , 14 - 16 Calculated virtual panel-reactive antibodies were computed using the Eurotransplant Reference Laboratory calculator. 17 KTR is considered sensitized if at least 1 anti-HLA antibody of >500 MFI was present at the D0 visit.…”

Section: Methodsmentioning

confidence: 99%

“…Interestingly, vaccination in organ transplant recipients has been widely discussed regarding its safety, although no evidence of increased rejection or autoimmunity rates has been shown. 7-11 Similar concerns have been raised with the advent of new mRNA vaccines. 12 Because mRNA vaccination is a novel technology whose safety has not yet been comprehensively studied in KTRs, establishing its safety regarding alloreactive adverse events is important.…”

mentioning

confidence: 88%

“…There were no safety signals in KTRs who received 3 doses of mRNA vaccines in the short-term follow-up. 7 Here, we show the 12-mo follow-up of a prospective, observational study aimed at assessing its immunogenicity and immunological safety (NCT05483725, EudraCT No. 2022-000319-30).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study

Petr,

Zahradka,

Modos

et al. 2024

Transplantation Direct

Self Cite

View full text Add to dashboard Cite

Background. Booster doses of SARS-CoV-2 mRNA vaccines are commonly used in kidney transplant recipients (KTRs). However, there is uncertainty regarding the waning of vaccination responses and immunological safety in KTRs. Methods. A total of 123 KTRs were included in the final analysis of this prospective observational cohort study. The aim was to evaluate the immunogenicity and immunological safety. SARS-CoV-2 antispike IgG antibodies and anti-HLA antibodies were measured at baseline and then at months 3, 6, and 12 after vaccination with the first booster dose (ie, the third vaccine dose). Antibodies against S1 and S2 subunits of SARS-CoV-2 were evaluated using an immunochemiluminescent assay (cutoff 9.5 AU/mL, sensitivity 91.2%, and specificity 90.2%). Anti-HLA antibodies were analyzed using single-antigen bead technology. Results. Seroconversion was reached in 65% of KTRs previously nonresponding to 2-dose mRNA vaccination; the overall seroconversion rate 3 mo after the first booster dose was 83%. Vaccination induced a durable humoral response, and the antibody levels were stable during the 12-mo study follow-up. Higher age (exponentiated beta coefficient [eβ] 0.97; 95% confidence interval [CI], 0.943-0.997) and a full dose of mycophenolate (eβ 0.296; 95% CI, 0.089-0.984) were negatively associated with SARS-CoV-2 IgG antibody levels, whereas better graft function (eβ1.021; 95% CI, 1.005-1.037) was associated positively. There were no systematic signs of anti-HLA antibody development after vaccination. However, during the follow-up, there was a nonsignificant signal of an increase in anti-HLA antibodies in those who developed COVID-19. Conclusions. Additional booster doses of SARS-CoV-2 mRNA vaccines induce durable antibody response even in a large subset of previous nonresponders and are not associated with the risk of allosensitization. Furthermore, a signal linking COVID-19 to the development of anti-HLA antibodies was observed, and this should be confirmed and further examined (NCT05483725).

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 88%